Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis

Company Overview

Agios Pharmaceuticals, Inc. is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations. Tibsovo (ivosidenib) is approved for treating relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation and for certain advanced cholangiocarcinoma patients. Idhifa (enasidenib) addresses AML patients bearing an IDH2 mutation. These targeted therapies represent some of the first metabolism-based oncology treatments on the market.

Beyond its approved products, Agios maintains a diverse pipeline in both oncology and rare genetic diseases. The company is developing mitapivat, a pyruvate kinase activator for chronic hemolytic anemias, in collaboration with Servier for ex-U.S. commercialization. Additional research programs leverage Agios’s expertise in metabolic targets to pursue next-generation candidates for hematologic malignancies and solid tumors. Agios markets its therapies directly in the United States and partners with global pharmaceutical companies for commercialization in Europe and other regions.

Agios went public in 2013 and has maintained its headquarters and core research operations in Cambridge. Leadership is currently headed by President and CEO Jackie Fouse, with Catherine Shacklett serving as Chief Financial Officer. The company continues to expand its scientific capabilities and strategic collaborations as it advances its mission of translating metabolism research into life-changing treatments.

Key Stats

• Today's Range: $26.62 to $27.51
• 50-Day Range: $24.43 to $35.20
• 52-Week Range: $22.24 to $46.00
• Volume: 212,897 shs
• Average Volume: 1.03 million shs
• Market Capitalization: $1.59 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.56
• Consensus Rating: Hold

Agios Pharmaceuticals Stock Analysis - MarketRank™

Agios Pharmaceuticals scored higher than 53% of companies evaluated by MarketBeat, and ranked 437th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Agios Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on no strong buy ratings, 6 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Agios Pharmaceuticals has a consensus price target of $41.56, representing about 53.7% upside from its current price of $27.04.

Amount of Analyst Coverage

Agios Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.19) to ($4.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Agios Pharmaceuticals is -3.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Agios Pharmaceuticals is -3.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Agios Pharmaceuticals has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.63% of the float of Agios Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Agios Pharmaceuticals has a short interest ratio ("days to cover") of 6.95.

Change versus previous month

Short interest in Agios Pharmaceuticals has recently increased by 7.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Agios Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Agios Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.30

News Sentiment

Agios Pharmaceuticals has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for Agios Pharmaceuticals this week, compared to 7 articles on an average week.

Search Interest

Only 1 people have searched for AGIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $520,405.00 in company stock.

Percentage Held by Insiders

5.40% of the stock of Agios Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Agios Pharmaceuticals has minimal institutional ownership at this time.

AGIO Stock Analysis - Frequently Asked Questions

How have AGIO shares performed this year?

Agios Pharmaceuticals' stock was trading at $27.22 at the beginning of 2026. Since then, AGIO shares have decreased by 0.7% and is now trading at $27.0390.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its quarterly earnings results on Wednesday, April, 29th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.81) by $0.12. The firm's revenue was up 137.7% compared to the same quarter last year.
Read the conference call transcript.

When did Agios Pharmaceuticals IPO?

Agios Pharmaceuticals (AGIO) raised $88 million in an IPO on Wednesday, July 24th 2013. The company issued 5,888,888 shares at $14.00-$16.00 per share.

Who are Agios Pharmaceuticals' major shareholders?

Top institutional shareholders of Agios Pharmaceuticals include Bank of New York Mellon Corp (0.31%), Pictet Asset Management Holding SA (0.22%), Assenagon Asset Management S.A. (0.11%) and SG Americas Securities LLC (0.10%). Insiders that own company stock include Jacqualyn A Fouse, Brian Goff, Sarah Gheuens, Cecilia Jones, James William Burns, Tsveta Milanova, David Scadden, Kaye I Foster-Cheek, Krishnan Viswanadhan and Theodore James Jr Washburn.
View institutional ownership trends.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Agios Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 4/29/2026
• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AGIO
• CIK: 1439222
• Web: www.agios.com
• Phone: (617) 649-8600
• Fax: N/A
• Employees: 390
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Agios Pharmaceuticals: $41.56
• High Price Target: $65.00
• Low Price Target: $28.00
• Potential Upside/Downside: +54.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.45
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$412.78 million
• Net Margins: -639.84%
• Pretax Margin: -641.38%
• Return on Equity: -34.11%
• Return on Assets: -31.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.19
• Quick Ratio: 13.59

Sales & Book Value

• Annual Sales: $54.03 million
• Price / Sales: 29.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $18.65 per share
• Price / Book: 1.44

Miscellaneous

• Outstanding Shares: 59,470,000
• Free Float: 56,261,000
• Market Cap: $1.60 billion
• Optionable: Optionable
• Beta: 0.58